GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Biogen Inc.
Biogen is a biotech company that has staked everything on the fight against Alzheimer's disease. Its stock chart is a dramatic story of controversial research results, regulatory battles, and an emotional roller coaster for investors.
Share prices of companies in the market segment - Neuro
Biogen is a biotech company specializing in the treatment of neurological diseases such as multiple sclerosis. We classify it in the Neuro sector. The chart below reflects the overall performance of this sector and the history of the company's risky bet on an Alzheimer's drug.
Broad Market Index - GURU.Markets
Biogen is one of the world's leading biotech companies, specializing in developing drugs to treat neurological diseases. It is a component of the GURU.Markets index. The chart below represents the market. See how advances in Alzheimer's drug development are impacting Biogen's stock.
Change in the price of a company, segment, and market as a whole per day
BIIB - Daily change in the company's share price Biogen Inc.
Biogen is a biotech company specializing in the treatment of neurological diseases such as multiple sclerosis. Its daily stock price fluctuations reflect the sector's inherent volatility and reaction to research results. This metric is a key component in the formulas on System.GURU.Markets, where it aids analysis.
Daily change in the price of a set of shares in a market segment - Neuro
Biogen Inc. is a pioneer in the treatment of neurological diseases. This chart highlights the high volatility of the biotech sector. Comparing it to BIIB, whose future hinges on the success of a controversial Alzheimer's drug, helps understand its unique risks.
Daily change in the price of a broad market stock, index - GURU.Markets
Biogen is one of the oldest biotech companies, specializing in the treatment of neurological diseases, particularly multiple sclerosis. Neurology is a risky field of research. The chart below illustrates the high volatility typical of the biotech sector.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Biogen Inc.
Biogen, a pioneering biotech company, has been in the spotlight over the past year due to the commercial launch of its new Alzheimer's drug. The year-over-year stock price performance, shown in the chart, reflects the market's assessment of the potential of this breakthrough, yet controversial, drug.
Annual dynamics of market capitalization of the market segment - Neuro
Biogen Inc. is a biotech company specializing in the treatment of neurological diseases such as multiple sclerosis. The company has faced challenges following the controversial launch of its Alzheimer's drug. This chart shows how the market is viewing its new strategy and research pipeline.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Biogen is a biotech company specializing in the treatment of complex neurological diseases. Its performance has been extremely volatile in recent years due to conflicting data on its Alzheimer's drug. This is a clear example of how scientific risks affect stocks regardless of the state of the economy.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Biogen Inc.
For Biogen, a biotech company focused on neuroscience, this chart is a history of scientific breakthroughs and setbacks. Each sharp monthly price fluctuation is often linked not to the market, but to the publication of clinical trial results for new drugs or regulatory decisions that determine the company's future.
Monthly dynamics of market capitalization of the market segment - Neuro
Biogen is a biotech company specializing in the treatment of neurological diseases such as multiple sclerosis and Alzheimer's disease. The dynamics of the neuroscience sector, shown in the chart, reflect the high risks and potential rewards of clinical trials. This allows us to assess how Biogen's successes and failures in drug development have impacted its position relative to the industry.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Shares of large biotech companies can be volatile due to news about clinical trials, especially in a complex area like Alzheimer's disease. The chart below shows the pulse of the market. Is Biogen living its own life, reacting to scientific data, or is its size forcing it to move with the market?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Biogen Inc.
Biogen, a biotech company specializing in neurological diseases, exhibits high volatility. Weekly stock performance depends on news about clinical trials, particularly Alzheimer's drugs, and regulatory decisions that could dramatically alter the company's outlook.
Weekly dynamics of market capitalization of the market segment - Neuro
As a large biotech company, Biogen often moves in response to overall sector sentiment. The chart allows us to compare its volatility with the industry's, distinguishing reactions to general news from sharp movements driven by Biogen-specific news about Alzheimer's drugs.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Biogen is a biotech company specializing in neuroscience, particularly in the treatment of multiple sclerosis and Alzheimer's disease. Its shares follow the rhythm of trial news. The chart will show how Biogen's performance is independent of the market, driven by its unique scientific data.
Market capitalization of the company, segment and market as a whole
BIIB - Market capitalization of the company Biogen Inc.
Biogen's market capitalization is a graph of hopes and disappointments in the fight against Alzheimer's disease. It reflects not only the stable business of treating multiple sclerosis but also the multibillion-dollar bets on developing drugs for complex neurological diseases. Its volatility reflects the risky nature of biotech research.
BIIB - Share of the company's market capitalization Biogen Inc. within the market segment - Neuro
Biogen is a biotech company specializing in developing drugs to treat neurological diseases such as multiple sclerosis and Alzheimer's disease. Its market share reflects both the success of its existing drugs and the promise of new breakthroughs. The chart shows the market's assessment of its scientific potential in this complex field.
Market capitalization of the market segment - Neuro
Biogen is a leading biotech company specializing in neurological diseases. The chart below shows the overall market capitalization of the entire biotech sector. Its volatile dynamics reflect the high risks and potential breakthroughs in treating diseases such as Alzheimer's and multiple sclerosis.
Market capitalization of all companies included in a broad market index - GURU.Markets
Biogen is a biotech pioneer specializing in the treatment of neurological diseases such as multiple sclerosis. Its market capitalization chart tells the story of scientific breakthroughs and setbacks in one of the most complex areas of medicine, revealing how the company is fighting for its share of the healthcare market.
Book value capitalization of the company, segment and market as a whole
BIIB - Book value capitalization of the company Biogen Inc.
For the biotech company Biogen, book value is its complex drug manufacturing plants and R&D centers. The chart below shows the material base for its scientific breakthroughs. Its dynamics reflect both investments in new production lines and write-offs following unsuccessful clinical trials.
BIIB - Share of the company's book capitalization Biogen Inc. within the market segment - Neuro
Biogen is a biotech company specializing in neurological diseases. Its strength lies in R&D, but producing complex biologics requires unique and expensive facilities. The asset share chart shows how the company is investing in its manufacturing capabilities to create drugs for complex diseases.
Market segment balance sheet capitalization - Neuro
Biotechnology is a world of contrasts. The graph shows the enormous factories of pharmaceutical giants. Biogen, a pioneer in the industry, also has its own production facilities. This makes it capital-intensive, but gives it control over the production of complex biological drugs.
Book value of all companies included in the broad market index - GURU.Markets
Biogen is a biotechnology pioneer specializing in the treatment of neurological diseases such as multiple sclerosis. The company's assets include cutting-edge research centers and manufacturing facilities. This chart shows the financial clout behind this company fighting brain diseases.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Biogen Inc.
Biogen Inc. is a neuroscience biotech company. Its valuation is close to book value, reflecting the loss of exclusivity for its legacy blockbusters and uncertainty about the success of its new Alzheimer's drug.
Market to book capitalization ratio in a market segment - Neuro
Biogen Inc. is a biotech company specializing in the treatment of neurological diseases such as multiple sclerosis. Its value is determined by its existing drug portfolio and the success of new developments. This chart shows how the market values its scientific potential relative to its tangible assets.
Market to book capitalization ratio for the market as a whole
Biogen is a biotech company specializing in the treatment of neurological diseases such as multiple sclerosis. Its value is determined by the success of its existing drugs and the potential of new developments in its pipeline. The chart shows how the market values this risky but potentially highly profitable business based on intellectual property.
Debts of the company, segment and market as a whole
BIIB - Company debts Biogen Inc.
Biogen, a biotech company specializing in neurological diseases, is using its financial structure to navigate patent cliffs and invest in risky R&D projects. This chart illustrates how the company is trying to find new blockbusters, including in the field of Alzheimer's disease, while managing its balance sheet.
Market segment debts - Neuro
Biogen is a biotech company specializing in the treatment of neurological diseases such as multiple sclerosis. Developing new drugs requires significant investment in R&D. The company's debt policy may reflect funding for clinical trials or acquisitions. This chart shows how Biogen manages capital as patents on old drugs expire and new drugs are being developed.
Market debt in general
Biogen Inc. is a biotech company specializing in the treatment of neurological diseases. Following the failure of its Alzheimer's drug and the loss of exclusivity for key drugs, the company is in a difficult situation. This chart helps assess how Biogen is managing its debt during this period of transformation and seeking new sources of growth.
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Biogen Inc.
Biogen, a biotech company specializing in neurological diseases, has faced challenges following the controversial launch of its Alzheimer's drug. This chart shows its financial health. Managing debt in this situation is critical to funding research into new, more promising drugs and restoring investor confidence.
Market segment debt to market segment book capitalization - Neuro
Biogen is a biotech company specializing in treating neurological diseases. This chart shows the debt burden in the neuroscience sector. It helps understand how companies in this complex and risky field finance their long-term research, especially after the ups and downs associated with Alzheimer's drugs.
Debt to book value of all companies in the market
Biogen is a biotech company specializing in neuroscience. This chart shows the overall debt level across the market. It allows one to compare Biogen's financial model, which requires massive investments in R&D with uncertain outcomes, with the more conservative debt policies of mature companies in the general economy.
P/E of the company, segment and market as a whole
P/E - Biogen Inc.
This chart for Biogen Inc. illustrates the complex valuation of a biotech company focused on neurological diseases. The company's profitability depends on the success of its drugs, particularly in the field of Alzheimer's disease. The metric reflects how investors weigh the enormous potential of its developments against the high risk of clinical trial failure.
P/E of the market segment - Neuro
Biogen is a leading biotech company specializing in developing drugs to treat neurological diseases such as multiple sclerosis and Alzheimer's. This chart illustrates the average valuation in the biotech sector, where investors evaluate scientific breakthroughs, clinical trial risks, and the potential of new drugs.
P/E of the market as a whole
Biogen is a biotech company specializing in the treatment of neurological diseases such as multiple sclerosis and Alzheimer's. Its valuation is heavily dependent on clinical trial results. This chart shows overall market sentiment. Comparing it with it reveals how Biogen's valuation is disconnected from market realities and relies solely on hopes for a scientific breakthrough.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Biogen Inc.
Biogen is a biotechnology company specializing in developing drugs to treat neurological diseases such as multiple sclerosis and Alzheimer's disease. This chart reflects market expectations for its scientific developments. The valuation is heavily dependent on clinical trial results and the commercial success of its drugs, particularly in the risky field of Alzheimer's treatment.
%20P%2FE%20Biogen%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Biogen-Inc.&v=1772513528631 "Chart of the company's future (projected) P/E Biogen Inc.")
Future (projected) P/E of the market segment - Neuro
Biogen is a biotech company specializing in developing drugs to treat neurological diseases such as multiple sclerosis and Alzheimer's disease. This chart compares the company's future profitability expectations with those of the pharmaceutical industry. It reflects how the market views their risky but potentially highly profitable pipeline.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772513528649 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
Biogen is a biotech company specializing in the treatment of neurological diseases such as multiple sclerosis and Alzheimer's disease. Its success is determined by the results of clinical trials. This graph of overall market expectations influences Biogen through the assessment of the entire biotech sector and investor risk appetite in anticipation of a scientific breakthrough.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513528679 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Biogen Inc.
Biogen is a biotechnology company specializing in developing drugs to treat neurological diseases such as multiple sclerosis and Alzheimer's disease. Its financial performance depends on the success of clinical trials and patent protection for key drugs. This chart reflects the high risks and potential breakthroughs in the fight against complex diseases.
Profit of companies in the market segment - Neuro
Biogen is a biotech company specializing in the treatment of neurological diseases such as multiple sclerosis. Its financial results are highly dependent on the success of clinical trials. This chart illustrates the high risk and potential rewards of the biotech sector, where a single drug breakthrough can dramatically change the profitability of the entire company and niche.
Overall market profit
Biogen is a biotech company specializing in the treatment of neurological diseases such as multiple sclerosis and Alzheimer's disease. The company's success depends on the results of clinical trials and the approval of new drugs. Its business is driven by science, not economic cycles, so its shares may perform differently from the overall market.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Biogen Inc.
Biogen is a biotech company historically focused on treating neurological diseases such as multiple sclerosis. This chart shows future profit expectations. Currently, analysts' forecasts are largely dependent on the commercial success of its new Alzheimer's drugs, which represents both a huge opportunity and a significant risk.
%20profit%20of%20the%20company%20Biogen%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Biogen-Inc.&v=1772513528722 "Graph of future (projected) profit of the company Biogen Inc.")
Future (predicted) profit of companies in the market segment - Neuro
Biogen is a biotechnology company specializing in developing drugs to treat neurological diseases such as multiple sclerosis and Alzheimer's disease. This chart shows the revenue forecast for the entire neuropharmaceutical industry. It reflects expectations for the success of clinical trials and the commercial potential of new treatments for brain diseases.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772513528749 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
Biogen is a biotech company specializing in the treatment of neurological diseases such as multiple sclerosis and Alzheimer's disease. Its success depends on the results of clinical trials and the approval of new drugs. General economic cycles, as illustrated here, have a lesser impact on the company but may influence pricing and reimbursement policies.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513528756 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Biogen Inc.
Biogen is a biotech company specializing in developing drugs to treat neurological diseases such as multiple sclerosis and Alzheimer's. This chart shows how investors value its revenue, which is heavily dependent on the success or failure of clinical trials for its risky but potentially breakthrough drugs.
P/S market segment - Neuro
Biogen is a biotech company specializing in developing drugs to treat neurological diseases such as multiple sclerosis and Alzheimer's disease. This is a high-risk, high-reward field. This chart reflects the average revenue estimate for the sector, helping to understand the expectations and risks the market is integrating into Biogen's innovation pipeline.
P/S of the market as a whole
Biogen is a biotech company specializing in developing drugs to treat neurological diseases such as multiple sclerosis and Alzheimer's. It's a high-risk, high-potential field. This market valuation chart helps us understand the premium investors are paying for the biotech's potentially revolutionary, yet risky, revenue.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Biogen Inc.
Biogen is a biotechnology company specializing in the treatment of neurological diseases such as multiple sclerosis and Alzheimer's disease. Future revenue depends on the success of its drugs and the results of clinical trials. This chart reflects investor expectations for the potential of its current and future drugs.
%20P%2FS%20Biogen%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Biogen-Inc.&v=1772513528831 "The graph of the company's future (projected) P/S Biogen Inc.")
Future (projected) P/S of the market segment - Neuro
Biogen is a biotech company specializing in the treatment of neurological diseases such as multiple sclerosis and Alzheimer's disease. Its future depends on the success of clinical trials of new drugs. This chart shows how the market values its future revenue, which is associated with high risks and potential breakthroughs in the treatment of complex diseases.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772513528870 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
Biogen is a biotech company specializing in the treatment of neurological diseases such as multiple sclerosis and Alzheimer's disease. Its success depends on breakthroughs in research. The overall market optimism, evident in the chart, creates a favorable environment for funding expensive clinical trials and increases the market's willingness to pay for innovative drugs.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513528889 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Biogen Inc.
Biogen is a biotechnology company specializing in developing drugs to treat neurological diseases such as multiple sclerosis and Alzheimer's disease. The company's revenue depends on sales of its key drugs. The chart shows the commercial success of these drugs, as well as issues related to patent expirations and clinical trial results.
Sales of companies in the market segment - Neuro
Biogen is a biotechnology company specializing in developing drugs for the treatment of neurological diseases. Its portfolio includes drugs for multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease. This chart shows the dynamics of the pharmaceutical market, where Biogen is betting on breakthrough innovations in one of the most complex areas of medicine.
Overall market sales
Biogen is a biotech company specializing in the treatment of neurological diseases such as multiple sclerosis. Its success depends on the effectiveness and sales of several key drugs. While this business is less susceptible to economic cycles, the overall economic situation, as reflected here, affects the solvency of healthcare systems.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Biogen Inc.
Biogen is a biotech company specializing in the treatment of neurological diseases such as multiple sclerosis and Alzheimer's disease. The company's future depends on the success of its new drugs and research. This chart reflects analyst consensus sales forecasts for Biogen's key drugs, including its controversial Alzheimer's drug.
%20sales%20of%20the%20company%20Biogen%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Biogen-Inc.&v=1772513528956 "Schedule of future (projected) sales of the company Biogen Inc.")
Future (projected) sales of companies in the market segment - Neuro
Biogen is a biotechnology company specializing in developing drugs to treat neurological diseases such as multiple sclerosis and Alzheimer's disease. The data in the chart shows the outlook for the pharmaceutical industry, allowing one to assess how the successes and failures of clinical trials for key drugs affect the outlook and volatility of Biogen's stock.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772513528972 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
Biogen Inc., a biotech company specializing in neurological diseases, sees this chart as a reflection of healthcare investments. The robust economic growth projected here provides funding for the development and deployment of expensive drugs to treat diseases such as multiple sclerosis and Alzheimer's.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513528979 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Biogen Inc.
Biogen is a biotech company specializing in the treatment of neurological diseases such as multiple sclerosis. Their success depends on the life cycle of their patented drugs and the success of new developments. This chart shows how the company is struggling with patent expirations on old blockbusters while striving to maintain profitability through new drugs.
Market segment marginality - Neuro
Biogen is a biotechnology company specializing in developing drugs to treat neurological diseases, primarily multiple sclerosis. This chart shows its profitability. The company's profitability is highly dependent on the success of its key drugs and its ability to bring new breakthrough treatments to market, such as those for Alzheimer's disease.
Market marginality as a whole
Biogen is a biotechnology company specializing in the treatment of neurological diseases. Its success depends on the results of clinical trials and the commercial potential of new drugs, particularly in the field of Alzheimer's disease. This overall market profitability graph has little to do with Biogen's fate, which is determined by science and regulators.
Employees in the company, segment and market as a whole
Number of employees in the company Biogen Inc.
Biogen is a biotech company specializing in the treatment of neurological diseases such as multiple sclerosis. This schedule can be highly volatile. Rapid staff increases can be associated with preparations for the launch of a new blockbuster, while layoffs often follow unsuccessful clinical trials or the loss of patent protection for key drugs.
Share of the company's employees Biogen Inc. within the market segment - Neuro
Biogen is one of the world's pioneering biotech companies specializing in developing drugs for the treatment of neurological diseases. This chart shows the percentage of leading neuroscience scientists and clinicians the company attracts. This is a testament to its deep scientific expertise and long-standing commitment to combating diseases like multiple sclerosis.
Number of employees in the market segment - Neuro
Biogen is a biotechnology company specializing in developing drugs to treat neurological diseases such as multiple sclerosis and Alzheimer's disease. This chart shows employment in the biotechnology sector. The dynamics of headcount, particularly research staff, reflect the successes and failures of clinical trials, which are key to the company's success.
Number of employees in the market as a whole
Biogen is a biotech company specializing in the treatment of neurological diseases such as multiple sclerosis. Their success depends on scientific breakthroughs and the ability of the healthcare system to cover expensive medications. This overall employment chart reflects the economic foundation that allows them to fund R&D and cover the costs of innovative therapies through insurance programs.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Biogen Inc. (BIIB)
Biogen is a leading biotech company specializing in the treatment of neurological diseases. This chart shows how the market values its scientific potential. Its high market capitalization per employee reflects the value of its drug portfolio and, more importantly, its R&D pipeline. The value lies in its patents, not in the number of employees in production.
%20of%20the%20company%20Biogen%20Inc.%20(BIIB)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Biogen-Inc.-BIIB&v=1772513529295 "Chart of market capitalization per employee (in thousands of dollars) of the company Biogen Inc. (BIIB)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
Biogen (BIIB) is a biotech company historically focused on neuroscience (multiple sclerosis) and now focusing on Alzheimer's drugs. Its value lies in R&D. This chart shows the market value per employee, reflecting the market's faith in its risky but potentially breakthrough pipeline.
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772513529301 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
Biogen is a biotech company specializing in developing drugs to treat neurological diseases such as multiple sclerosis and Alzheimer's disease. This chart shows a high market value per employee, reflecting the value of their research and the potential of their drugs.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513529326 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Biogen Inc. (BIIB)
Biogen is a biotech company specializing in the treatment of neurological diseases (such as multiple sclerosis). It's an R&D-intensive business. This chart shows how effectively the company monetizes its blockbuster drugs. It reflects how much revenue each employee generates and is heavily dependent on the success of their R&D pipeline and generic competition.
%20Chart%20Biogen%20Inc.%20(BIIB)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Biogen-Inc.-BIIB&v=1772513529358 "Company Profit Per Employee (in thousands of dollars) Chart Biogen Inc. (BIIB)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
Biogen is a biotech company with historical strengths in neurosciences (multiple sclerosis) and the controversial Alzheimer's disease. This chart shows the benchmark for "Neuro" (Biotech). This benchmark reflects the "blockbuster business." Employee profitability is high, as it depends on R&D breakthroughs and patents for complex drugs.
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772513529400 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
Biogen is a biotech company specializing in the treatment of neurological diseases such as multiple sclerosis. It's a research-intensive business with high development risks but also high potential returns. This chart shows how scientific breakthroughs and successful drugs enable the company to achieve high profitability despite research setbacks.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513529443 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Biogen Inc. (BIIB)
Biogen is a biotech company specializing in the treatment of neurological diseases, specifically multiple sclerosis. This chart illustrates the specifics of the pharmaceutical business. High revenue per employee is often the result of the success of several blockbuster drugs that generate the company's primary revenue.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Biogen-Inc.-BIIB&v=1772513529485 "Sales chart per company employee Biogen Inc. (BIIB)")
Sales per employee in the market segment - Neuro
Biogen is a biotech company historically focused on neuroscience (a leader in multiple sclerosis treatment). It is currently actively investing in Alzheimer's drugs. It is an R&D-intensive business. This chart shows the industry average per employee revenue. It helps assess the productivity of their R&D machine.
Sales per employee for the market as a whole
Biogen is a biotech company specializing in complex neurological diseases, particularly multiple sclerosis. Their business is focused on R&D and sales of high-margin biologics. This metric reflects how their team of scientists generates revenue from their blockbusters, albeit aging, and new, controversial drugs (for Alzheimer's).
Short shares by company, segment and market as a whole
Shares shorted by company Biogen Inc. (BIIB)
Biogen is a biotech company specializing in neurological diseases, specifically multiple sclerosis. This chart shows bearish bets. Bears are shorting Biogen, pointing to the failure of its controversial Alzheimer's drug (Aduhelm) and the loss of market share of its leading MS drugs due to competition and patent expirations.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Biogen-Inc.-BIIB&v=1772513529574 "Short Shares Chart for the Company Biogen Inc. (BIIB)")
Shares shorted by market segment - Neuro
Biogen (BIIB) is a biotech company historically focused on treating multiple sclerosis and now betting on Alzheimer's drugs. This chart shows bets against the entire biotech sector. The rising bets against the industry reflect deep investor skepticism about the commercial success of new Alzheimer's drugs and the failure of research.
Shares shorted by the overall market
Biogen is a biotech company focused on complex diseases, primarily neurological ones (Alzheimer's). Its stock depends on breakthroughs in R&D. This indicator reflects overall market pessimism. When fears mount, investors often avoid biotechs with binary risk (drug success or failure), preferring more predictable sectors.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Biogen Inc. (BIIB)
Biogen is a biotech giant that has historically dominated multiple sclerosis treatment. Now all eyes are on their Alzheimer's drugs. This oscillator measures the response to binary events. Full FDA approval of their Alzheimer's drug could trigger explosive growth (above 70). A trial failure would plunge it into panic mode (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Biogen-Inc.-BIIB&v=1772513529672 "RSI 14 indicator chart for the company's stock Biogen Inc. (BIIB)")
RSI 14 Market Segment - Neuro
Biogen is a biotech company specializing in developing treatments for complex neurological diseases such as multiple sclerosis and Alzheimer's disease (Aduhelm, Leqembi). This chart reflects the collective sentiment in the biotech sector. It helps distinguish BIIB volatility related to trial results from the overall industry trend.
RSI 14 for the overall market
Biogen (BIIB) is a biotech company specializing in the treatment of complex neurological diseases such as multiple sclerosis and Alzheimer's. This chart measures overall market euphoria. Biotech stocks like BIIB often move not with the market, but on drug approval news. However, general panic or euphoria still influences their valuation.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast BIIB (Biogen Inc.)
Biogen is a biotech company historically focused on treating multiple sclerosis. Currently, all eyes are on its controversial but potentially revolutionary Alzheimer's drugs. This chart reflects the enormous uncertainty and analyst expectations regarding the commercial success of these new drugs.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-BIIB-Biogen-Inc.&v=1772513529788 "A chart showing analyst consensus forecasts for the expected stock price. BIIB (Biogen Inc.)")
The difference between the consensus estimate and the actual stock price BIIB (Biogen Inc.)
Biogen is a biotech company that has historically specialized in treating multiple sclerosis. Their current focus is on Alzheimer's drugs (Aduhelm, Leqembi). This chart shows analysts' confidence in the commercial success of this risky but potentially huge therapy. It reflects the gap between the target price and the current price.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-BIIB-Biogen-Inc.&v=1772513529803 "A chart showing the difference between the consensus forecast and the actual stock price. BIIB (Biogen Inc.)")
Analyst consensus forecast for stock prices by market segment - Neuro
Biogen, a biotech company historically strong in multiple sclerosis treatments, is now betting on a breakthrough in Alzheimer's disease. This chart shows analysts' overall expectations across the biotech sector. It reflects whether experts believe Alzheimer's therapy will succeed or fail.
Analysts' consensus forecast for the overall market share price
Biogen (BIIB) is a biotech company historically focused on complex neurological diseases like multiple sclerosis. They are now making bold bets on Alzheimer's disease. This chart shows the overall risk appetite in the market, reflecting how willing investors are to fund breakthrough but risky research.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Biogen Inc.
Biogen is a biotech company historically focused on neuroscience, with a dominant franchise in multiple sclerosis. In recent years, their main bet has been on controversial and expensive Alzheimer's drugs. This chart reflects this risky R&D gamble. It weighs the erosion of their legacy franchises against the commercial potential of their breakthrough but complex Alzheimer's drugs.
AKIMA Market Segment Index - Neuro
Biogen is a biotech company that has historically been a leader in multiple sclerosis (MS) treatments and is now betting all-in on Alzheimer's disease. This composite metric evaluates R&D. The graph shows the segment average. This benchmark: how does Biogen's risky (Alzheimer's) R&D strategy differentiate it from the average pharma company?
The AKIM Index for the overall market
Biogen is a biotech company historically focused on neuroscience (multiple sclerosis) and, more recently, controversial Alzheimer's drugs. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this innovative but risky scientific story, driven by the laws of biotech, compares to overall economic trends.
